This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

On February 17, 2026, ACT Capital Management disclosed a new position in TG Therapeutics (NASDAQ:TGTX), acquiring 268,875 shares worth $8,015,164. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, ACT Capital Management established a new position in TG Therapeutics during the prior quarter, acquiring 268,875 shares. The quarter-end value of the stake stood at $8,015,164, reflecting the full impact of the new holding’s valuation. What else to know ...